{"url_path":"/sec/tela/8-k/2026-06-11/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1561921/0001104659-26-072931-index.html","accession_number":"0001104659-26-072931","cik":"0001561921","ticker":"TELA","issuer_name":"TELA Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1561921/0001104659-26-072931-index.html","primary_entity_key":"0001561921","primary_entity_name":"TELA Bio, Inc."},"word_count":301,"has_tables":true,"body_markdown":"**Item 5.07**\n**Submission of Matters to a Vote of Security Holders.**\n\n \n\nAs of April 24, 2026, the record date for the Annual Meeting,\nthere were 44,765,928 outstanding shares of the Company’s common stock, par value $0.001 per share. The Annual Meeting was conducted\nvirtually, and the following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders\nat the Annual Meeting, which are described in detail in the Company’s Proxy Statement.\n\n \n\n(a)            *Proposal\n1 - Election of Class I Directors*. Each of Joseph Capper, Betty Jo Rocchio and William Plovanic were elected to the Board to\nserve as Class I directors until the 2029 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed,\nor their earlier death, resignation, retirement, disqualification or removal, as follows:\n\n \n\nName \nFor \nWithheld \nBroker Non-Votes\n\nJoseph Capper \n27,244,482 \n567,207 \n5,650,509\n\nBetty Jo Rocchio \n27,595,955 \n215,734 \n5,650,509\n\nWilliam Plovanic \n27,497,453 \n314,236 \n5,650,509\n\n \n\n(b)            *Proposal\n2 - Ratification of Independent Registered Public Accountant*. The appointment of KPMG LLP as the Company’s independent registered\npublic accounting firm for the 2026 fiscal year was ratified, as follows:\n\n \n\nVotes For  \nVotes Against  \nAbstentions  \nBroker Non-Votes \n\n 33,443,686  \n 17,890  \n 622  \n - \n\n \n\n(c)            *Proposal\n3 - Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers.*The stockholders\napproved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as follows:\n\n \n\nVotes For  \nVotes Against  \nAbstentions  \nBroker Non-Votes \n\n 20,891,695  \n 6,900,032  \n 19,962  \n 5,650,509 \n\n \n\n(d)           *Proposal\n4 - Approval of an amendment to the TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan to, among other things, increase\nthe authorized shares issuable thereunder by 3,500,000 shares.*The Plan Amendment was approved, as follows:\n\n \n\nVotes For  \nVotes Against  \nAbstentions  \nBroker Non-Votes \n\n 27,256,266  \n 538,830  \n 16,593  \n 5,650,509"}